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Prostate cancer (CaP) is a common cancer, and histopathological
evidence of this cancer is found in up to 50% of men between
70–80 years of age (Sheldon et al, 1980), but in only a fraction of
these, the disease becomes symptomatic and has clinical relevance
(Gittes, 1991). Identifying individuals at risk for developing this
common malignancy has obvious clinical applications, from both
personal and national health care perspectives. Familial clustering
and early onset disease are well known risk factors predisposing to
CaP. The relative risk (RR) for developing CaP in first degree rela-
tives of CaP patients ranges from 1.65 to 3.3, with increased RR
associated with an earlier age at diagnosis and having more than
one affected family member (Carter et al, 1992; Whittemore et al,
1995). These observations suggest an inherited predisposition to
CaP, which seems to occur in about 5–10% of all CaP patients
(Carter et al, 1992). The genes that underlie this genetic suscepti-
bility remain largely unknown. Clustering of breast, ovarian and
prostate cancer has been reported (Tulinius et al, 1992; Anderson
and Badzioch, 1993; Sellers et al, 1994; Easton et al, 1997),
suggesting a role for BRCA1 (Arason et al, 1993; Briana et al,
1996) and BRCA2 (Struewing et al, 1997) genes in CaP predispo-
sition. Indeed, epidemiological studies estimated the RR for
developing CaP in BRCA1 mutation carriers is 3.33 (Ford et al,
1994, Easton et al, 1995), and that of first degree relatives of
BRCA2 mutation carriers at 4.6 (Sigurdsson et al, 1997). Among
Jewish people, three predominant mutations within these two
genes occur: 185delAG, 5382InsC (BRCA1) and 6174delT
(BRCA2). These three mutations occur in the majority of individ-
uals at risk for developing breast and ovarian cancer, and also in
about 2.5% of the general Ashkenazi (East European) Jews, and
the 185delAG mutation in up to 1% of non-Ashkenazi Jews (Bar-
Sade et al, 1998). Indeed, the lifetime risk for developing CaP in
Ashkenazi BRCA1 or BRCA2 mutation carriers was estimated at
16% (Struewing et al, 1997). However, direct mutational analysis
of 60 unselected Jewish Ashkenazi CaP patients did not reveal any
BRCA1 or BRCA2 mutation carrier (Lehrer et al, 1998).
Considering the putative role of BRCA1 as a tumour suppressor
gene and in keeping with Knudson’s two hit model of tumour
development (Knudson, 1971), BRCA1 involvement in the tumori-
genic process could also be indirectly demonstrated by allelic loss
(Loss of Heterozygosity – LOH) of BRCA1 linked markers. LOH
analysis utilizing such markers facilitates elucidation of the role of
BRCA1 in familial prostate cancer, independent of the type of an
inherited predisposing mutation. Indeed, LOH at the BRCA2 locus
is commonly encountered in advanced CaP (Melamed et al, 1997).
To test the notion that BRCA1 or BRCA2 are involved in genetic
predisposition to CaP, we determined the rate of the predominant
germline mutations in 174 unselected Jewish CaP patients and, in
addition, searched for allelic losses at the BRCA1 locus in a subset
of patients with a family history of CaP.
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Summary Inherited predisposition occurs in 5–10% of all prostate cancer (CaP) patients, but the genes involved in conferring genetic
susceptibility remain largely unknown. Several lines of evidence indicate that germline mutations in BRCA1 and BRCA2 might be associated
with an increased risk for CaP. Three mutations in these two genes (185delAG and 5382InsC (BRCA1) and 6174delT (BRCA2) occur in about
2.5% of the general Ashkenazi population, and the 185delAG BRCA1 mutation, in up to 1% of non-Ashkenazi Jews. In order to assess the
contribution of these germline mutations to prostate cancer in Jewish Israeli patients, we tested 174 unselected prostate cancer patients
(95 of Ashkenazi origin) for these mutations by PCR amplification and modified restriction enzyme digests. Patient’s age range was 45–81
years (median 66), and in 24 (14.4%) the disease was diagnosed prior to 55 years of age. Nineteen (11%) and 12 (6.9%) patients had a first
or second degree relative with CaP or breast cancer, respectively. Overall, five mutation carriers were detected: 2/152 (1.3%) 185delAG,
2/104 (2%) 5382InsC, and 1/158 (0.6%) 6174delT. In all carriers, the disease was diagnosed after the age of 55, and only one of them had a
family history of breast and CaP. In addition, no allelic losses at the BRCA1 locus were demonstrated in 17 patients with a family history of
CaP, using seven microsatellite markers. We conclude that the rate of the predominant Jewish BRCA1 and BRCA2 mutations in CaP patients
does not significantly differ from that of the general population, and that mutational inactivation of the BRCA1 is rare in familial CaP. Thus,
germline BRCA1 and BRCA2 mutations probably contribute little to CaP occurrence, to inherited predisposition, and to early onset disease in
Jewish individuals. © 2000 Cancer Research Campaign
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Patients’ characteristics and tumour material
All patients with a clinical and histopathological diagnosis of CaP
who were treated at either the Rabin, Sheba or the Wolfson
Medical Centers during 1998, were eligible for participation. The
study was approved by the institutional review board (IRB) and all
patients signed an informed consent form. All consenting patients
filled a detailed questionnaire (available from the authors upon
request), that includes demographic data, past medical history, age
at diagnosis, family history of cancer, especially breast, ovarian
and/or prostate. In addition, for patients who underwent radical
retropubic prostatectomy, disease stage and grade were noted.
Based on the criteria applied for other familial cancers, at least one
first degree relative with prostate or related cancer (breast and
ovarian), or more than two second degree relatives with cancer of
which one is CaP, breast or ovarian cancer, were classified as
familial CaP (Schneider et al, 1983). Paraffin blocks of familial
CaP patients were also retrieved.
DNA extraction
Anticoagulated peripheral blood was withdrawn by venepuncture,
and DNA was extracted using standard techniques. DNA was
extracted from paraffin embedded tissue as described by Greer and
coworkers (Greer et al, 1991), with the slight modification of
prolonged incubation at 37°C for 72 hours, with three additions of
proteinase K (0.2 mg ml–1). Unstained 5–10 mm slides were used
for DNA extraction, separating tumorous from non-tumorous
tissue from the same slide. The final extraction volume was 150 ml
and 3–5 ml were used as template in the polymerase chain reaction
(PCR) (see below).
Mutation analysis of the predominant Jewish mutations
in BRCA1 and BRCA2
Mutational analyses for the three predominant mutations
(185delAG, 5382InsC in BRCA1 and 6174delT in BRCA2), were
carried out by restriction enzyme digest of amplified PCR prod-
ucts using modified amplification primers, to generate novel
restriction sites, followed by restriction enzyme analysis to distin-
guish the mutant from the wild-type allele, as previously described
(Abeliovich et al, 1997), and adopted by us (Bar-Sade et al, 1998).
PCR with chromosome 17 markers for allelic loss
determination
PCRs were performed in a final volume of 15 ml containing 3–5 ml
template, 10 picomoles of each primer, 200 mM of each TTP, CTP
and GTP and 1 mM of ATP, and a radioactively labelled 32P ATP,
103 standard PCR buffer (1.5 mM MgCl2) 0.2 U of thermostable
DNA polymerase (Perkin-Elmer Corp., Norwalk, CT). Thermal
cycling was accomplished by PTC-100/60 thermocycler (MJ
Research Inc., Watertown, MA). The cycling profile included: an
initial denaturation at 94°C for 5 minutes, followed by 34 cycles at
55°C for 3 minutes, extension at 72°C for 1 minute and denatura-
tion at 94°C for 45 seconds, with a final extension cycle at 72°C
for 5 minutes. Following cycling 4 ml of gel loading buffer
(0.025% Bromophemol blue, 0.025% Xylene cyanol and 30%
glycerol) were added to the PCR reaction, and 5 ml were loaded
onto a 6% sequencing gel, ran for 1.5 to 3 hours at 70W, and
autoradiographed for 24 to 72 hours at room temperature using
Fuji X-ray films. The microsatellite markers used were previously
published with respect to LOH within the BRCA1 region (Futreal
et al, 1994) and were purchased from Research Genetics
(Huntsville, AL, USA). Primer loci and designation and their rela-
tive linear ordering are as follows: D17S250, D17S579 (both
localize centromeric to the BRCA1 locus), D17S855, D17S1322,
D17S1325 (all internal to the BRCA1 locus) and D17S1323,
D17S1327 (both telomeric to the BRCA1 locus). LOH was scored
after visual assessment of the autoradiograms, and the allele sizes
were inferred from running an M13 sequence in adjacent lanes.
Statistical analyses
Comparisons of the rates of the founder Jewish mutations between
CaP patients and historical controls (Struewing et al, 1997) were
performed using Fisher’s exact test.
RESULTS
Patients’ characteristics
Of 174 consenting patients, 95 (54.6%) were of Ashkenazi origin
and the rest (n = 79), non-Ashkenazis. Median age at diagnosis
was 66 years (range 45–81 years); In 24/174 (13.8%) diagnosis
was made prior to age 55 years, in 19 (10.9%) there was a family
history of CaP in a first or second degree relative, and in 12 (6.9%)
there was a family history of breast cancer. The majority of
patients (105/174, 60%) had stage T2 disease, with 46 (26.4%)
with stage 3 disease, and 6 (3.4%) with metastatic disease. About
half of the patients (82/174 48.3%) had moderately differen-
tiated disease (Gleason score 5–7), and 12 (6.9%) had poorly
differentiated disease (Gleason score 8–10).
Germline mutational analyses
For technical reasons, mutational analyses were not successful for
all mutations in all samples. The presence of the 185delAG
BRCA1 mutation was analysed in 152 patients (87 Ashkenazis),
and 2 mutation carriers were detected (1.3% of all patients, 2.3%
of the Ashkenazis). The 5382InsC mutation was successfully
tested for in 104 patients (60 Ashkenazis) and was detected in
2 patients (1.9% of all patients, 3.3% of the tested Ashkenazis).
The 6174delT BRCA2 mutation was tested in 158 patients (86
Ashkenazis) and one carrier was found (0.6% of all patients, 1.1%
of Ashkenazis).
No mutation was detected in any patient in whom the diagnosis
was made prior to the age of 55 years, and only one of the carriers
(the 6174delT mutation carrier) had a family history of CaP and
breast cancer.
Allelic loss analyses
In 17 of the patients having a family history of CaP or breast
cancer, the pathological slides could be retrieved. All 17 patients
were informative with at least two polymorphic markers, and at
least one of these markers was an intragenic BRCA1 gene marker.
No difference between the allelic pattern of the tumorous and non-
tumorous tissue in any of the markers was noted. Figure 1 shows a
few examples of the allelic patterns. Notably, non-specific bands
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ture used. Moreover, the need to use 35 amplification cycles for
the paraffin embedded tumour tissue was deemed prohibitive to
evaluation of allele intensity as an indicator of allelic loss.
Statistical analyses
We limited ourselves to analyses of Ashkenazi patients only, since
the numbers in the literature refer to this ethnic group. There were
no statistically significant differences in the carrier rate of the
185delAG BRCA1 and 6174delT BRCA2 mutations between the
two groups, and the differences between the general population
and the CaP patients was statistically significant for the 5382InsC
BRCA1 mutation (Table 1).
DISCUSSION
In the present study, the involvement of the BRCA1 and BRCA2
genes in inherited predisposition to prostate cancer (CaP) was
evaluated by two approaches, direct mutational analyses and
allelic loss determination. Jewish Israeli patients with an apparent
inherited predisposition to CaP did not display allelic loss
involving the BRCA1 locus on chromosome 17. This conclusion
should be drawn tentatively, given the technical limitations of the
present study: use of paraffin embedded tissue, no microdissection
to separate tumorous from non-tumorous tissue, low annealing
temperature, and using 35 PCR cycles. These realities do limit the
ability to detect subtle allelic losses, however, the similar allelic
patterns displayed in tumour and non-tumorous tissue, might indi-
cate that somatic inactivation of the BRCA1 gene is infrequent in
Jewish familial CaP patients. Given the published rate of 17q
allelic loss in sporadic prostate cancer which ranges from 15%
(Watanabe et al 1998) to 61% (Deubler et al, 1997), it is surprising
that allelic loss was not demonstrated in any of our selected group
of patients. It may signify that the underlying molecular mecha-
nisms involved in tumour initiation may follow an alternative
pathway in inherited than sporadic CaP. Interestingly, allelic losses
at 17q in CaP seem to target a region that lies distal to the BRCA1
gene, implicating a novel tumour suppressor gene, distinct from
the BRCA1 gene, in CaP tumorigenesis (Williams et al, 1996).
The rate of two of the three predominant Jewish mutations
in BRCA1 and  BRCA2 in Ashkenazi CaP patients did not
significantly differ from the rate in the general Jewish Ashkenazi
population (Struewing et al, 1997). Furthermore, other parameters
usually presumed to be associated with inherited predisposition,
such as disease diagnosed prior to age 55 or family history of
cancer, were either not present, or affected only one of five
germline mutation carriers, respectively. The least common Jewish
BRCA1 mutation, 5382InsC, was statistically more prevalent in
CaP patients than in the general population, but this difference is
based on a relatively small number of mutation carriers, and
should be interpreted cautiously. These data are in agreement with
other studies published showing a low rate of involvement of the
BRCA1 and BRCA2 gene germline mutations in CaP pathogenesis
in ethnically diverse populations, and in Ashkenazi Jews, in partic-
ular. A study from Washington state reported only one prostate
cancer case with a germline BRCA1 mutation (185delAG) with a
questionable family history, and an additional five rare allelic
polymorphisms in other familial prostate cancer cases (Langston et
al, 1996). An additional study failed to identify an increased risk of
breast cancer in relatives of patients with prostate cancer (Issacs et
al, 1995). One BRCA1 germline mutation carrier with CaP and
familial cancer was reported among 24 Japanese CaP patients, no
185delAG or 6174delT mutation carriers were detected among 60
Ashkenazi CaP patients (Lehrer et al, 1998), and one 6174delT
BRCA2 mutation carrier was found among 47 Jewish Ashkenazi
individuals from 18 families with familial CaP (Wilkens et al,
1999). Recently, three mutation carriers (two with the 185delAG
and one harbouring 6174delT) were identified among 87 unse-
lected prostate cancer patients from Israel (Hubert et al, 1999).
Interestingly, three of 87 age-matched healthy controls were also
mutation carriers. These direct mutational analyses studies are not
in line with the reported increased relative risk for developing CaP
among patients with a family history of breast and ovarian cancer.
Furthermore, in an Icelandic population, where a single predomi-
nant mutation (999del5) in BRCA2 exists, the mutation was six
times more prevalent among CaP patients (2.7%) as among the
general population (0.4%) (Johannesdottir et al, 1996). In addition,
if we limit our analysis to the Ashkenazi patients studied herein,
the overall carrier rate of one of the predominant mutations is 5/87
(5.7%), a rate double that of the general Ashkenazi population.
In conclusion, in Jewish CaP patients, germline mutations in the
BRCA1 and BRCA2 genes seem to contribute little to the tumori-
genic process, and somatic inactivation of the BRCA1 genes
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Figure 1 Representative LOH patterns of four markers from several
individuals. The marker tested is shown on the left; the tumorous tissue (T)
and the non-tumorous tissue (N) are marked at the bottom. As is evident,
allelic patterns and signal intensities are comparable for each marker in the
tumour and non-tumorous tissue
Table 1 Comparisons between the carrier rate of the predominant Jewish
mutations in BRCA1 and BRCA2 in the general Jewish Ashkenazi population
(Struewing et al, 1997) and the Ashkenazi CaP patients tested in this study
Mutation 185delAG 5382InsC 6174delT
(gene) BRCA1 BRCA1 BRCA2
CaP 2/87 (2.3%) 2/60 (3.3%) 1/86 (1.1%)
General
population 41/5318 (0.77%) 20/5318 (0.37%) 59/5087
(1.16%)
P value 0.15 (NS) 0.02 0.6 (NS)
NS, not significant.occurs infrequently in familial Jewish CaP patients. From the
current available data it seems that men harbouring one of the
predominant Jewish germline mutations do not have an increased
risk for developing early onset CaP. The lifetime risk for CaP
development in Jewish BRCA1 and BRCA2 mutation carriers and
the occurrence rate of these mutations in unselected CaP patients
remains to be determined in a larger, prospective study.
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